<DOC>
	<DOC>NCT00288509</DOC>
	<brief_summary>The aim of this study is to assess longer term safety and effectiveness of Dysport®.</brief_summary>
	<brief_title>Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Subjects enrolled in the Y4752120051 study, who have completed all study visits up to Week 12, or up to Week 4 in the event of an early withdrawal Returned to pretreatment status as judged by the Investigator Pure anterocollis or pure retrocollis Known antibodies to botulinum toxin type A Requirement for botulinum toxin injections to site(s) other than the neck and unable to avoid such treatment for the duration of the study Known significant underlying swallowing or respiratory abnormality which might be exacerbated by botulinum toxin treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>